Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report

Most common sites of metastasis of urothelial carcinoma (UC) are lungs, liver, lymph nodes and bone. Pembrolizumab, a humanized monoclonal antibody directed against programmed cell death protein-1 (PD-1), represents an effective second-line therapy for advanced UC. Radiotherapy has been shown to ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonfante, Giulia, Fantinel, Emanuela, Masini, Cristina, Bergamaschi, Franco, Micali, Salvatore, Rocco, Bernardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566948/
https://www.ncbi.nlm.nih.gov/pubmed/33088719
http://dx.doi.org/10.1016/j.eucr.2020.101444
_version_ 1783596224738230272
author Bonfante, Giulia
Fantinel, Emanuela
Masini, Cristina
Bergamaschi, Franco
Micali, Salvatore
Rocco, Bernardo
author_facet Bonfante, Giulia
Fantinel, Emanuela
Masini, Cristina
Bergamaschi, Franco
Micali, Salvatore
Rocco, Bernardo
author_sort Bonfante, Giulia
collection PubMed
description Most common sites of metastasis of urothelial carcinoma (UC) are lungs, liver, lymph nodes and bone. Pembrolizumab, a humanized monoclonal antibody directed against programmed cell death protein-1 (PD-1), represents an effective second-line therapy for advanced UC. Radiotherapy has been shown to induce a mechanism of immunogenic cell death (ICD) resulting in immune memory and advantageous systemic effects. We present the first case of breast metastasis (BM) from a UC described in literature who had an exceptional response to second-line therapy with pembrolizumab in association with radiotherapy, showing the efficacy of combining immunotherapy and radiotherapy even in patients with atypical metastatic sites.
format Online
Article
Text
id pubmed-7566948
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75669482020-10-20 Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report Bonfante, Giulia Fantinel, Emanuela Masini, Cristina Bergamaschi, Franco Micali, Salvatore Rocco, Bernardo Urol Case Rep Oncology Most common sites of metastasis of urothelial carcinoma (UC) are lungs, liver, lymph nodes and bone. Pembrolizumab, a humanized monoclonal antibody directed against programmed cell death protein-1 (PD-1), represents an effective second-line therapy for advanced UC. Radiotherapy has been shown to induce a mechanism of immunogenic cell death (ICD) resulting in immune memory and advantageous systemic effects. We present the first case of breast metastasis (BM) from a UC described in literature who had an exceptional response to second-line therapy with pembrolizumab in association with radiotherapy, showing the efficacy of combining immunotherapy and radiotherapy even in patients with atypical metastatic sites. Elsevier 2020-10-09 /pmc/articles/PMC7566948/ /pubmed/33088719 http://dx.doi.org/10.1016/j.eucr.2020.101444 Text en © 2020 The Authors. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Bonfante, Giulia
Fantinel, Emanuela
Masini, Cristina
Bergamaschi, Franco
Micali, Salvatore
Rocco, Bernardo
Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report
title Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report
title_full Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report
title_fullStr Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report
title_full_unstemmed Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report
title_short Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report
title_sort exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566948/
https://www.ncbi.nlm.nih.gov/pubmed/33088719
http://dx.doi.org/10.1016/j.eucr.2020.101444
work_keys_str_mv AT bonfantegiulia exceptionalresponsetoimmunotherapyinassociationwithradiotherapyinpatientwithbreastmetastasisfromurothelialcarcinomaacasereport
AT fantinelemanuela exceptionalresponsetoimmunotherapyinassociationwithradiotherapyinpatientwithbreastmetastasisfromurothelialcarcinomaacasereport
AT masinicristina exceptionalresponsetoimmunotherapyinassociationwithradiotherapyinpatientwithbreastmetastasisfromurothelialcarcinomaacasereport
AT bergamaschifranco exceptionalresponsetoimmunotherapyinassociationwithradiotherapyinpatientwithbreastmetastasisfromurothelialcarcinomaacasereport
AT micalisalvatore exceptionalresponsetoimmunotherapyinassociationwithradiotherapyinpatientwithbreastmetastasisfromurothelialcarcinomaacasereport
AT roccobernardo exceptionalresponsetoimmunotherapyinassociationwithradiotherapyinpatientwithbreastmetastasisfromurothelialcarcinomaacasereport

Ejemplares similares